Impact of glutathione metabolism on zinc homeostasis in Saccharomyces cerevisiae

Zinc availability from zinc-enriched yeast studied with an in vitro digestion/Caco-2 cell culture model

BACKGROUND

Organic zinc sources for the treatment of zinc deficiency or as a supplement to a specific diet are increasingly needed. Zinc-enriched yeast (ZnYeast) biomass is a promising nutritional supplement for this essential micronutrient. However, these products are not yet authorized in the European Union and a clear position from the European Food Safety Authority on the use of ZnYeast as a zinc supplement is pending, demanding more data on its bioavailability.

OBJECTIVE

The study aimed to produce a ZnYeast based on a Saccharomyces genus (S. pastorianus Rh), characterize its zinc enrichment quota, cellular distribution of zinc, and evaluate its zinc bioavailability after human digestion by comparing it to commonly used inorganic and organic zinc supplements (ZnO, ZnSO4, zinc gluconate, and zinc aspartate).

METHOD AND MAIN FINDINGS

The zinc-enriched S. pastorianus Rh contained 5.9 ± 1.0 mg zinc/g yeast, which was predominantly localized on the cell surface according to its characterization on the microscale with scanning electron microscopy (SEM) with energy-dispersive X-ray (EDX). Combined experiments with a human in vitro digestion model and the in vitro intestinal cell model Caco-2 showed that intestinal zinc bioavailability of digested yeast biomass was comparable to the other zinc supplements, apart from ZnO, which was somewhat less bioavailable. Moreover, zinc released from digested ZnYeast was available for biological processes within the enterocytes, leading to mRNA upregulation of metallothionein, a biomarker of intestinal zinc status, and significantly elevated the cellular labile zinc pool.

CONCLUSIONS

Our findings demonstrated that ZnYeast represents a suitable nutritional source for organically bound zinc and highlighted optimization strategies for future production of dietary ZnYeast.

At the metal-metabolite interface in Aspergillus fumigatus: towards untangling the intersecting roles of zinc and gliotoxin

Cryptic links between apparently unrelated metabolic systems represent potential new drug targets in fungi. Evidence of such a link between zinc and gliotoxin (GT) biosynthesis in Aspergillus fumigatus is emerging. Expression of some genes of the GT biosynthetic gene cluster gli is influenced by the zinc-dependent transcription activator ZafA, zinc may relieve GT-mediated fungal growth inhibition and, surprisingly, GT biosynthesis is influenced by zinc availability. In A. fumigatus, dithiol gliotoxin (DTG), which has zinc-chelating properties, is converted to either GT or bis-dethiobis(methylthio)gliotoxin (BmGT) by oxidoreductase GliT and methyltransferase GtmA, respectively. A double deletion mutant lacking both GliT and GtmA was previously observed to be hypersensitive to exogenous GT exposure. Here we show that compared to wild-type exposure, exogenous GT and the zinc chelator N,N,N',N'-tetrakis(2-pyridinylmethyl)-1,2-ethanediamine (TPEN) inhibit A. fumigatus ΔgliTΔgtmA growth, specifically under zinc-limiting conditions, which can be reversed by zinc addition. While GT biosynthesis is evident in zinc-depleted medium, addition of zinc (1 µM) suppressed GT and activated BmGT production. In addition, secretion of the unferrated siderophore, triacetylfusarinine C (TAFC), was evident by A. fumigatus wild-type (at >5 µM zinc) and ΔgtmA (at >1 µM zinc) in a low-iron medium. TAFC secretion suggests that differential zinc-sensing between both strains may influence fungal Fe3+ requirement. Label-free quantitative proteomic analysis of both strains under equivalent differential zinc conditions revealed protein abundance alterations in accordance with altered metabolomic observations, in addition to increased GliT abundance in ΔgtmA at 5 µM zinc, compared to wild-type, supporting a zinc-sensing deficiency in the mutant strain. The relative abundance of a range of oxidoreductase- and secondary metabolism-related enzymes was also evident in a zinc- and strain-dependent manner. Overall, we elaborate new linkages between zinc availability, natural product biosynthesis and oxidative stress homeostasis in A. fumigatus.

Zinc homeostasis in the secretory pathway in yeast

It is estimated that up to 10% of proteins in eukaryotes require zinc for their function. Although the majority of these proteins are located in the nucleus and cytosol, a small subset is secreted from cells or is located within an intracellular compartment. As many of these compartmentalized metalloproteins fold to their native state and bind their zinc cofactor inside an organelle, cells require mechanisms to maintain supply of zinc to these compartments even under conditions of zinc deficiency. At the same time, intracellular compartments can also be the site for storing zinc ions, which then can be mobilized when needed. In this review, we highlight insight that has been obtained from yeast models about how zinc homeostasis is maintained in the secretory pathway and vacuole.

Biguanide is a modifiable pharmacophore for recruitment of endogenous Zn2+ to inhibit cysteinyl cathepsins: review and implications

Excessive activities of cysteinyl cathepsins (CysCts) contribute to the progress of many diseases; however, therapeutic inhibition has been problematic. Zn²⁺ is a natural inhibitor of proteases with CysHis dyads or CysHis(Xaa) triads. Biguanide forms bidentate metal complexes through the two imino nitrogens. Here, it is discussed that phenformin (phenylethyl biguanide) is a model for recruitment of endogenous Zn²⁺ to inhibit CysHis/CysHis(X) peptidolysis. Phenformin is a Zn²⁺-interactive, anti-proteolytic agent in bioassay of living tissue. Benzoyl-L-arginine amide (BAA) is a classical substrate of papain-like proteases; the amide bond is scissile. In this review, the structures of BAA and the phenformin-Zn²⁺ complex were compared in silico. Their chemistry and dimensions are discussed in light of the active sites of papain-like proteases. The phenyl moieties of both structures bind to the "S2" substrate-binding site that is typical of many proteases. When the phenyl moiety of BAA binds to S2, then the scissile amide bond is directed to the position of the thiolate-imidazolium ion pair, and is then hydrolyzed. However, when the phenyl moiety of phenformin binds to S2, then the coordinated Zn²⁺ is directed to the identical position; and catalysis is inhibited. Phenformin stabilizes a "Zn²⁺ sandwich" between the drug and protease active site. Hundreds of biguanide derivatives have been synthesized at the 1 and 5 nitrogen positions; many more are conceivable. Various substituent moieties can register with various arrays of substrate-binding sites so as to align coordinated Zn²⁺ with catalytic partners of diverse proteases. Biguanide is identified here as a modifiable pharmacophore for synthesis of therapeutic CysCt inhibitors with a wide range of potencies and specificities. Phenformin-Zn²⁺ Complex.

Glutathione from recovered glucose as ingredient in antioxidant nanocapsules for triggered flavor delivery

Glucose recovered via enzymatic hydrolysis of rayon fibers was used for glutathione production by S. cerevisiae. Glutathione was used in combination with HSA and silk fibroin for ultrasound assisted nanocapsules production. Triggered release of flavor substances and antioxidant properties of the nanocapsules was demonstrated.